Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance
| Autor: | Manubai Nagamani, Vicken Sepilian |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Blood Glucose medicine.medical_specialty endocrine system diseases medicine.medical_treatment Adipokine Type 2 diabetes Statistics Nonparametric 03 medical and health sciences 0302 clinical medicine Insulin resistance Internal medicine medicine Humans Insulin Testosterone Obesity Glucose tolerance test 030219 obstetrics & reproductive medicine medicine.diagnostic_test Adiponectin business.industry Dehydroepiandrosterone Sulfate nutritional and metabolic diseases Obstetrics and Gynecology Glucose Tolerance Test Luteinizing Hormone medicine.disease Polycystic ovary Endocrinology Area Under Curve Intercellular Signaling Peptides and Proteins Female Insulin Resistance Rosiglitazone business 030217 neurology & neurosurgery medicine.drug Polycystic Ovary Syndrome |
| Zdroj: | Journal of the Society for Gynecologic Investigation. 12(2) |
| ISSN: | 1071-5576 |
| Popis: | Adiponectin is an adipokine that is decreased in obesity and type 2 diabetes. Women with polycystic ovarian syndrome (PCOS) are obese and are at risk for type 2 diabetes. The objective of the current study was to investigate the relationship of adiponectin to obesity and insulin resistance in women with PCOS and severe insulin resistance.Thirty women with PCOS and acanthosis nigricans indicating severe insulin resistance were included in the study. Eleven body mass index (BMI)-matched women with normal ovulatory cycles served as controls. Fasting glucose, insulin, and adiponectin levels were measured, and a standard oral glucose tolerance test (OGTT) with insulin levels was performed. To further investigate the role of insulin sensitivity on adiponectin levels, 10 women with PCOS were treated with 4 mg rosiglitazone daily for 6 months and adiponectin levels were measured before and after treatment.Fasting insulin levels (33.5 +/- 3.8 microU/mL; P.001) and insulin area under the curve (AUC) during OGTT (536.2 +/- 70.5 microU/mL; P.01) were higher in women with PCOS, while glucose levels were similar to controls. Adiponectin levels were lower (P.01) in women with PCOS (5.6 +/- 2.6 microg/mL) compared with controls (8.5 +/- 3.9 microg/mL). There was a significant negative correlation between adiponectin levels and fasting insulin levels (r = -0.40, P = .02), insulin AUC during OGTT (r = -0.47, P = .008), fasting glucose levels (r = -0.45, P = .01), and glucose AUC during OGTT (r = -0.51, P = .003). There was no correlation between BMI and serum adiponectin (r = -0.12, P = .508) in women with PCOS, while there was a negative correlation (r = -0.746, P = .013) in controls. There was a significant (P.01) increase in adiponectin levels when treated with rosiglitazone, despite unchanged BMI.These results indicate that in women with PCOS and severe insulin resistance, insulin sensitivity appears to be the major determinant of adiponectin levels rather than adiposity. Low adiponectin levels may predict women with PCOS who are at high risk for developing type 2 diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink